Adenosine Receptor A3 - Drugs In Development, 2021
- $ 3500
- April 2024
- 96 pages
Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Glaucoma, Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Psoriasis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Coronavirus Disease 2019 (COVID-##), Diabetic Nephropathy, Erectile Dysfunction, Female Sexual Dysfunction, Inflammatory Pain, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Ocular Hypertension, Plaque Psoriasis (Psoriasis Vulgaris), Post-Operative Pain, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Ulcerative Colitis.